Navigation Links
Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
Date:11/7/2008

KANSAS CITY, Mo., Nov. 7 /PRNewswire/ -- In refusing to a request for a special shareholders meeting to consider the removal and replacement of its current directors, management of Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts ("ADRs) are traded on NASDAQ, has apparently decided that the preservation of their jobs and positions in the company outweigh the right of shareholders to meet for the purpose of considering their job performance.

On October 16, 2008, a group of Trinity Biotech ADR holders sent a request to Trinity Biotech calling for the convening of a special meeting of Trinity Biotech shareholders to consider the removal of the current Trinity Biotech directors and their replacement by a slate nominated by the ADR holders who requested the meeting. Thomas Reidy, a member of the group, announced today that company management had advised him by letter dated November 5, 2008 that they would not call the special meeting as requested.

In their refusal letter, the Trinity Biotech directors stated that their denial was based on a determination that the ADR holders, as contrasted with the ordinary shares they represent, do not have the authority under Irish law to call the meeting.

Commenting on Trinity Biotech's refusal to call the special meeting, Mr. Reidy stated that he was "disappointed but certainly not surprised" by the position taken by current management. Mr. Reidy pointed out that the group's original letter requesting the special meeting contains a demand that the Trinity Biotech directors take alternative steps to effectuate the special meeting if management is of the opinion that the requesting ADR holders did not have the authority under Irish law to convene the meeting. Management's refusal letter was silent regarding these alternative steps.

Mr. Reidy stated, "Management's refusal to honor our request or to take the alternative steps proposed to bring our proposal before the company's shareholders can only be viewed as a further step by management to remain entrenched in their positions and beyond any accountability to the owners of the company."

Mr. Reidy continued, "Trinity Biotech management has benefited by accessing American and European equity capital markets through the sale of ADRs. As a result over 90% of the company's ownership is evidenced by ADRs. Management has welcomed our investment but now chooses to disenfranchise us when their performance is called into question and their jobs are on the line. Apparently, management has concluded that their past performance is such that they would be unable to convince a majority of shareholders to vote for their retention."

Mr. Reidy went on to say, "This latest decision only further demonstrates that this board has lost touch with its fiduciary responsibilities. As we have said in the past, this board needs to be removed and replaced by directors who are committed to acting in the best interest of the company and its owners."

Mr. Reidy stated that he would continue in his efforts to bring about the special shareholder meeting. Such efforts might include converting ADRs into the ordinary shares they represent. Mr. Reidy anticipated that other ADR holders would join him in these efforts.

Safe Harbor Statement

Statements in this release that are not historical are forward-looking statements, including statements regarding Mr. Reidy's beliefs, expectations, hopes or intentions regarding the future. It is important to note that actual outcomes and results could differ materially from forward-looking statements. Mr. Reidy assumes no obligation to update any forward-looking statement.

Contact: Thomas J. Reidy, 816-260-8476


'/>"/>
SOURCE Thomas J. Reidy
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
2. Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008
3. Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
4. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
7. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
9. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
10. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
11. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):